Related Experiment Videos
Aromatase inhibitors and inactivators for breast cancer therapy
1Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway. plon@haukeland.no
Abstract:
Aromatase inhibitors and inactivators are increasingly important to the therapy of advanced breast cancer in postmenopausal women. These compounds are also currently being evaluated in the adjuvant setting and may have potential in breast cancer prevention. In addition to the recent clinical results, experimental research with development of aromatase 'knockout' mice as well as certain clinical observations in individuals lacking this enzyme have deepened our understanding of estrogens outside of the field of reproduction. Such information should help us to further develop this type of therapy in breast cancer and, in particular, extend our understanding of the lack of complete cross-resistance between aromatase inhibitors and inactivators. Clinically, third-generation aromatase inhibitors and inactivators have shown superiority compared with conventional treatment in advanced postmenopausal breast cancer with respect to second-line (tamoxifen failures) as well as first-line therapy. The fact that tamoxifen is noncurative in metastatic disease but improves long-term survival in the adjuvant setting suggests that even modest improvements in therapy of advanced disease may be translated into survival benefits in patients with early disease. In addition, these novel compounds with lack of complete cross-resistance extend the scope of using sequential treatment options to maximise the duration of optimal endocrine therapy in metastatic breast cancer disease.
Insights
Aromatase inhibitors and inactivators are crucial for treating advanced breast cancer in postmenopausal women. Research shows these therapies offer superior outcomes and potential for prevention, improving endocrine therapy effectiveness.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Aromatase inhibitors and inactivators are vital in treating advanced breast cancer in postmenopausal women.
- Their role is expanding to adjuvant therapy and potential breast cancer prevention.
- Research, including aromatase knockout mice, enhances understanding of estrogen's role beyond reproduction.
Purpose of the Study:
- To review the clinical efficacy and potential of aromatase inhibitors and inactivators in breast cancer therapy.
- To explore the implications of new research on estrogen biology for therapeutic development.
- To discuss the lack of complete cross-resistance between different classes of aromatase-targeting drugs.
Main Methods:
- Review of clinical trial results for third-generation aromatase inhibitors and inactivators.
- Analysis of experimental research, including genetically modified animal models.
- Examination of clinical observations in individuals with enzyme deficiencies.
Main Results:
- Third-generation aromatase inhibitors and inactivators demonstrate superiority over conventional treatments in advanced postmenopausal breast cancer.
- These agents show effectiveness in both first-line and second-line (post-tamoxifen failure) settings.
- The lack of complete cross-resistance allows for extended sequential treatment options.
Conclusions:
- Aromatase inhibitors and inactivators represent a significant advancement in breast cancer therapy for postmenopausal women.
- These drugs offer improved outcomes in advanced disease and potential benefits in early-stage disease and prevention.
- Understanding drug resistance mechanisms can optimize sequential endocrine therapy strategies.